The trial, conducted at RDC Clinical in Brisbane, Australia, between July and December 2025, was prospectively registered with ClinicalTrials.gov and approved by an independent ethics committee. Participants were randomly allocated in a one-to-one ratio to receive either the active softgel capsules or an identical placebo containing only sunflower oil. The active capsules delivered 28 to 30 milligrams of mixed carotenoids daily, a blend of lutein, zeaxanthin, alpha-carotene, beta-carotene, and lycopene, the same pigments that give carrots, tomatoes, and leafy greens their vivid colors. Investigators, participants, and even the statistician analyzing the data remained blinded to group assignments throughout, and compliance was impressively high, averaging near or above the full prescribed dose in both arms.

The scientific rationale for the study rests on decades of work showing that carotenoids are among the skin’s most important dietary allies. Skin aging unfolds through two overlapping pathways: intrinsic aging, driven by genetics, metabolism, and hormonal shifts, and extrinsic aging, driven by ultraviolet radiation, smoking, and pollution. Both converge on the production of reactive oxygen species, unstable molecules that damage proteins, lipids, and DNA, degrading the collagen and elastic fibers that keep skin firm and resilient. Carotenoids counter this assault in two ways, directly neutralizing free radicals and switching on the body’s own antioxidant enzymes, including superoxide dismutase, catalase, and glutathione peroxidase. When ingested, they accumulate in the skin, where they also absorb specific wavelengths of ultraviolet light and dissipate the energy as harmless heat, providing a form of internal photoprotection.

The timing of the intervention was no accident. Women in their forties and fifties face a particularly punishing hormonal transition for their skin. Estrogen normally stimulates fibroblasts to produce collagen and promotes hyaluronic acid synthesis, which locks moisture into the tissue and limits water escaping through the surface. As estrogen declines through perimenopause and menopause, collagen production falters while its breakdown accelerates; skin collagen is estimated to fall by roughly thirty percent during the first five years of menopause, and a further two percent each year afterward. The result is thinning, dryness, and a weakening of the skin barrier, precisely the deficits the Brisbane team set out to measure with objective instruments rather than subjective impressions.

Those instruments were put to work at baseline, week six, and week twelve. A high-resolution imaging system, the A-One Smart Pro, photographed each participant’s face under normal, ultraviolet, and polarized lighting, using algorithms to score wrinkles, elasticity, moisture, sebum, pigmentation, pore size, and temperature. A separate DermaLab Combo system measured transepidermal water loss, or TEWL, the gold-standard indicator of skin barrier function, and used high-frequency ultrasound to gauge dermal thickness. Meanwhile, a non-invasive spectroscopy device called the Veggie Meter quantified the carotenoids actually present in each participant’s skin, providing a direct readout of whether the supplement was reaching its target tissue.

The headline result was a striking negative. At both week six and week twelve, there were no significant differences between the active and placebo groups on any of the visible aging parameters, meaning the supplement did not visibly smooth wrinkles, tighten pores, or brighten pigmentation over the study period. One unexpected wrinkle in the data even favored placebo: the control group showed a larger improvement in elasticity scores over time. The researchers acknowledge that the trial may have been underpowered for visible outcomes, since their sample size calculation was based on effect estimates drawn from a physiologically different study of eye health, an acknowledged limitation that introduces uncertainty into the power analysis.

Beneath the surface, however, the story changed dramatically. Skin carotenoid scores in the supplement group surged by 48.1 percent from baseline, rising significantly by week six and widening further by week twelve, while the placebo group remained essentially flat. Because dietary carotenoid intake, tracked with a validated questionnaire, was similar in both groups, the increase clearly reflected the bioavailability of the capsules themselves, which the lipophilic compounds carried alongside sunflower oil. This matters because only an estimated five to thirty percent of dietary carotenoids are typically absorbed, and the rapid enrichment of skin tissue validates both the formulation and the delivery system.

Two structural markers also moved in the right direction. Transepidermal water loss, which rises when the skin barrier leaks moisture, fell by 31.3 percent from baseline in the supplement group, a change that was statistically significant compared with placebo and supported by a repeated-measures analysis showing an overall treatment effect. Dermal thickness, measured by ultrasound, increased by 11.9 percent in the active group versus 3.6 percent with placebo, a between-group difference in change that also reached significance. The authors suggest that the reduced water loss may stem from carotenoid protection of lipid membranes in the stratum corneum, while the thickening dermis points toward enhanced collagen deposition in the extracellular matrix, since carotenoids such as beta-carotene, lutein, and lycopene have been shown to protect collagen from oxidative degradation and to support its synthesis.

The safety profile was reassuring. Thirteen adverse events were reported across the study, most of them mild, self-limiting gastrointestinal complaints such as bloating, reflux, and loose stools, with similar rates in both groups. There were no serious adverse events and no withdrawals attributed to the treatment, and the harmless skin yellowing known as carotenoderma, a theoretical concern with high carotenoid intakes, did not appear. The researchers caution that whether the 31.3 percent reduction in water loss translates into perceptible relief from dryness cannot be confirmed, because the trial included no patient-reported outcome measures of skin comfort, and that the structural changes detected on ultrasound had not yet ripened into visible surface improvements within twelve weeks.

What the study ultimately delivers is a biologically grounded, cautiously optimistic case rather than a cosmetic miracle. The authors conclude that CaroRite may support antioxidant status, barrier function, and dermal structure, key parameters for long-term skin health that can precede detectable changes in visible aging, and they call for longer trials, alternative doses, combination formulations, and populations with more advanced photoaging, as well as men and older adults excluded from this study. For consumers tempted by the promise of a wrinkle-free capsule, the message is tempered: twelve weeks of carotenoids made these women’s skin measurably healthier under the hood, but erasing the lines etched by decades of time, gravity, and sunlight remains a far slower and harder project than nourishing the living tissue underneath.

Subject of Research: Effects of oral mixed-carotenoid supplementation on skin health and visible signs of aging in healthy middle-aged women

Article Title: CaroRite™ for improving skin health and the visible signs of aging – a randomised, double-blind, placebo-controlled trial

Article References: CaroRite™ for improving skin health and the visible signs of aging – a randomised, double-blind, placebo-controlled trial. (n.d.). https://doi.org/10.3389/fragi.2026.1858090

Image Credits: AI Generated

DOI: 10.3389/fragi.2026.1858090

Keywords: carotenoids, skin aging, CaroRite, transepidermal water loss, dermal thickness, randomized controlled trial, nutricosmetics, skin barrier, lutein, beta-carotene, lycopene, antioxidants

The research, led by Faezeh Khorasanizadeh of the Department of Radiology at Razi Hospital, Tehran University of Medical Sciences, together with colleagues in dermatology, epidemiology, and biostatistics, and in collaboration with Ximena Wortsman of the Universidad de Chile, a pioneer in cutaneous ultrasound, enrolled eighteen patients with newly biopsy-confirmed morphea. Every participant had at least one clinically active plaque at baseline. The investigators deliberately designed the protocol to be practical: rather than imaging every lesion, they selected the most clinically probable active plaque in each patient and compared it with adjacent or contralateral normal skin serving as an internal control. Each patient then underwent grayscale ultrasound, color Doppler ultrasound, and shear-wave elastography at the start of the study and again after six months of treatment, alongside standardized clinical scoring. The study received ethical approval from the institutional review board of Tehran University of Medical Sciences and was conducted in accordance with the Declaration of Helsinki, with written informed consent obtained from all participants and guardians of minors.

The technical logic behind the imaging approach is worth unpacking. High-frequency grayscale ultrasound can resolve the individual layers of the skin with millimeter precision, allowing radiologists to measure dermal thickness, the hallmark of fibrotic thickening in morphea, and hypodermal thickness, which reflects the fat layer beneath. In active lesions, inflammation and edema typically thicken the dermis and can alter the echotexture of the subcutis. Color Doppler ultrasound adds a functional dimension by detecting blood flow; increased vascularity within and beneath a plaque is considered a marker of subclinical inflammatory activity that may persist even when the skin surface appears quiescent. Shear-wave elastography, the most technically sophisticated of the three, works by generating shear waves, a form of transverse mechanical vibration, within the tissue and measuring the speed at which they propagate. Because stiffer tissue transmits shear waves faster than soft tissue, the technique yields a quantitative estimate of tissue elasticity in kilopascals, turning the subjective sensation of hardened skin into a reproducible number.

After six months of follow-up, the results told a clear and clinically meaningful story. Dermal thickness, measured ultrasonographically, decreased significantly alongside a significant fall in mean clinical scores, with p values below 0.05. The LoSAI activity score dropped from a mean of 4.28 plus or minus 3.28 at baseline to 1.44 plus or minus 1.75 after treatment, while the LoSDI damage score declined from 11.39 plus or minus 7.38 to 9.56 plus or minus 6.77. Hypodermal thickness also decreased and skin elasticity increased slightly over the six months, but neither of these secondary changes reached statistical significance. The pattern makes biological sense: inflammation-driven dermal thickening responds to immunosuppressive therapy within months, whereas fibrotic remodeling of the subcutis and restoration of elastic properties are slower processes that may lag behind clinical improvement or, in the case of established damage, never fully reverse.

Perhaps the most intriguing findings emerged from the correlation analyses. Hypodermal thickness correlated negatively with the Physician Global Assessment of Damage, with a Spearman rho of -0.410 and a p value of 0.027, and positively with the LoSAI activity index, with rho of 0.513 and p of 0.004. Hypodermal thickness was also positively correlated with the Physician Global Assessment of Activity before treatment began. After therapy, hypodermal stiffness measured by elastography correlated positively with the LoSDI damage index. Taken together, these relationships suggest that the subcutaneous fat layer, often overlooked in favor of the dermis, carries real diagnostic information: a thicker hypodermis tracks with active disease, while stiffer subcutaneous tissue tracks with accumulated damage. This positions elastography not merely as a research curiosity but as a potential bridge between the activity and damage domains that clinicians must distinguish when deciding whether to escalate, continue, or taper therapy.

Not every result favored the new technology, and the authors were candid about the limitations. When radiologists and dermatologists independently rated disease activity using shear-wave elastography and color Doppler, the inter-rater agreement was poor, with a kappa of just 0.053, barely above chance. This discordance likely reflects the steep learning curve of cutaneous ultrasound, differences in probe positioning and pressure, and the absence of universally standardized scoring protocols across specialties. It is a sobering reminder that a measurement technique is only as objective as the protocol governing its use. The authors also emphasized that their cohort was small, with only eighteen patients, all of whom had plaque-type or linear morphea, the most common subtypes. Generalizing to rarer variants such as generalized, deep, or pansclerotic morphea will require larger and more diverse cohorts, and the six-month follow-up window may be too short to capture slower changes in elasticity and subcutaneous architecture.

Why does an objective biomarker matter so much for morphea specifically? Current treatment typically involves systemic corticosteroids combined with methotrexate or, increasingly, other immunomodulators, a regimen that carries real toxicity and demands months of commitment. Because clinical scores are subjective and damage can masquerade as activity, physicians risk both overtreating patients whose disease has already burned out and undertreating those with smoldering subclinical inflammation that continues to cause irreversible fibrosis. Ultrasound-based measures could change this calculus in several ways: by providing early, quantitative evidence of response within weeks rather than months; by identifying subclinical activity that warrants continued therapy even when the skin looks better; and by serving as surrogate endpoints in clinical trials, where the rarity of morphea has long made adequately powered studies difficult. Prior work by Wortsman and colleagues on the Ultrasound Morphea Activity Scoring system, and by other groups applying shear-wave elastography in both localized and systemic scleroderma, has laid the groundwork, but this study is among the first to track patients longitudinally through treatment with a multimodal protocol.

The study also fits into a broader movement in dermatology toward quantitative, imaging-based assessment of skin disease. Thermal imaging has been explored for detecting inflammation in localized scleroderma, dermoscopy offers clues to disease stage, and 50-megahertz ultrasound has documented improvement after ultraviolet A1 phototherapy. In systemic sclerosis, elastography is being evaluated as a measure of skin strain and fibrosis severity, raising the possibility of a shared imaging vocabulary across the sclerosing diseases. A recent consensus statement on the diagnosis and treatment of sclerosing skin diseases underscores how much remains unsettled in monitoring these conditions, and the authors of the current study position their work as a preliminary but prospective step toward filling that gap with tools that are already available in most radiology departments.

For now, the take-home message is measured but promising. In this preliminary prospective cohort, dermal thickness measured with high-frequency ultrasound emerged as the strongest candidate for an objective marker of treatment response in morphea, while color Doppler and shear-wave elastography showed potential as adjunctive tools whose clinical utility remains exploratory. The authors themselves stress that validation in larger cohorts is essential before these techniques enter routine practice, and the poor inter-rater agreement highlights the need for standardized acquisition and scoring protocols, ideally with dedicated training for both radiologists and dermatologists. Still, the direction of travel is unmistakable. If subsequent studies confirm these findings, the era of guessing whether a morphea plaque is truly quiet could give way to an era in which a handheld probe, a quantitative elasticity map, and a few millimeters of measured dermis tell clinicians exactly what the immune system is doing beneath the skin, and whether the treatment they have chosen is actually working.

Subject of Research: Ultrasound and shear-wave elastography for monitoring treatment response in morphea

Article Title: Ultrasound and shear-wave elastography as a tool for evaluating response to treatment of morphea: a preliminary report of a prospective study

Article References: Khorasanizadeh, F., Sharifi, M. A., Vahabi, S. M., Ansari, M. S., Ghandi, N., Hosseini, F., Etesami, I., & Wortsman, X. (2026). Ultrasound and shear-wave elastography as a tool for evaluating response to treatment of morphea: a preliminary report of a prospective study. Archives of Dermatological Research, 318(1), Article 457. https://doi.org/10.1007/s00403-026-04919-7

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04919-7

Keywords: morphea, localized scleroderma, ultrasound, shear-wave elastography, color Doppler, dermal thickness, LoSAI, LoSDI, treatment response, biomarkers, dermatology, skin fibrosis